Company type | Public |
---|---|
ISIN | US5324571083 |
Industry | Pharmaceutical |
Founded | 1876 |
Founder | Eli Lilly |
Headquarters | Indianapolis, Indiana, U.S. |
Key people | |
Products | Pharmaceutical drugs |
Revenue | US$34.12 billion (2023) |
US$6.46 billion (2023) | |
US$5.24 billion (2023) | |
Total assets | US$64.01 billion (2023) |
Total equity | US$10.77 billion (2023) |
Owner | Lilly Endowment (10.8%) |
Number of employees | c. 43,000 (2023) |
Website | lilly |
Footnotes / references [1][2][3][4][5] |
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union Army veteran of the American Civil War for whom the company was later named.[6]
As of October 2024, Lilly is the most valuable drug company in the world with a $842 billion market capitalization, the highest valuation ever achieved to date by a drug company.[7] The company is ranked 127th on the Fortune 500 with revenue of $34.12 billion.[8] It is ranked 221st on the Forbes Global 2000 list of the world's largest publicly-traded companies[9] and 252nd on Forbes' list of "America's Best Employers".[10] It is recognized as the top entry-level employer in Indianapolis.[11]
Lilly is known for its clinical depression drugs Prozac (fluoxetine) (1986), Cymbalta (duloxetine) (2004), and its antipsychotic medication Zyprexa (olanzapine) (1996). The company's primary revenue drivers are the diabetes drugs Humalog (insulin lispro) (1996) and Trulicity (dulaglutide) (2014).[12]
Lilly was the first company to mass-produce both the polio vaccine, developed in 1955 by Jonas Salk, and insulin. It was one of the first pharmaceutical companies to produce human insulin using recombinant DNA, including Humulin (insulin medication), Humalog (insulin lispro), and the first approved biosimilar insulin product in the U.S., Basaglar (insulin glargine).[13] Lilly brought exenatide to market—the first of the GLP-1 receptor agonists[14]—followed by blockbuster drugs in the same class such as Mounjaro and Zepbound (tirzepatide).[7]
As of 1997, it was both the largest corporation and the largest charitable benefactor in Indiana.[15] In 2009, Lilly pleaded guilty for illegally marketing Zyprexa and agreed to pay a $1.415 billion penalty that included a criminal fine of $515 million, the largest ever in a healthcare case and the largest criminal fine for an individual corporation ever imposed in a U.S. criminal prosecution of any kind at the time.[16][17]
Lilly is a full member of the Pharmaceutical Research and Manufacturers of America[18] and the European Federation of Pharmaceutical Industries and Associations (EFPIA).[19]
Barnes
was invoked but never defined (see the help page).Pollack2
was invoked but never defined (see the help page).usdoj-2009
was invoked but never defined (see the help page).:1
was invoked but never defined (see the help page).